Document is current

Article History

Received: 19 April 2021

Accepted: 19 May 2021

First Online: 12 June 2021

Declarations

:

: Sara Tolaney has the following COI to disclose: institutional research funding: AstraZeneca, Lilly, Merck, Nektar, Novartis, Pfizer, Genentech/Roche, Immunomedics, Exelixis, Bristol-Myers Squibb, Eisai, Nanostring, Cyclacel, Odonate, Seattle Genetics; advisor/consultant: AstraZeneca, Lilly, Merck, Nektar, Novartis, Pfizer, Genentech/Roche, Immunomedics, Bristol-Myers Squibb, Eisai, Nanostring, Puma, Sanofi, Celldex, Paxman, Puma, Silverback Therapeutics, G1 Therapeutics, AbbVie, Anthenex, OncoPep, Outcomes4Me, Kyowa Kirin Pharmaceuticals, Daiichi-Sankyo, Samsung Bioepsis Inc. Denise Yardley has the following COI to disclose: Consultant/advisory role: Novartis, Genentech/Roche, Daiichi Sankyo/Lilly, Eisai, Celgene, Biotheranostics, NanoString Technologies, Bristol-Myers Squibb; Speakers’ Bureau: Novartis, Genentech/Roche; Research funding (to institute): AstraZeneca, Genentech/Roche, Syndax, Novartis, MedImmune, Lilly, Medication, Pfizer, Eisai, Tesaro, Macrogenics, AbbVie, Immunomedics, Daiichi Sankyo, Merck, Clovis Oncology, Oncothyreon, InventisBio; Travel/Accommodations/Expenses: Novartis, Genentech/Roche. Ron Bose has the following COI to disclose: Research grant from Puma Biotechnology and consulting for Genentech (advisory board for the MyPathway trial). VK Gadi has the following COI to disclose: Genentech, Agendia, Signalone Bio; Consulting: Puma, Seattle Genetics, Pfizer, Novartis; Equity/ownership: SEngine Precision Medicine. Kelly Marcom has the following COI to disclose: Genentech/Roche: DSMB. Kathy Albain has the following COI to disclose: Contracted research funding to institution: Astra Zeneca, Daiichi Sankyo, ISPY2 Consortium; Other: member, Data Safety and Monitoring Committee, Daiichi Sankyo. Nadine Tung has the following COI to disclose: Research funding from Astra-Zeneca and Myriad, Inc. Rita Nanda has the following COI to disclose: past 3 years: Advisory Board: Aduro, Athenex, Clovis, Daiichi Sankyo, Inc, Genentech, Immunomedics, MacroGenics, Merck, Pfizer, Seattle Genetics; DSMB: G1 Therapeutics; Research Funding (to institution): AstraZeneca, Celgene, Corcept Therapeutics, Genentech/Roche, Immunomedics, Merck, OBI Pharm, Inc., Odonate Therapeutics, Pfizer, Seattle Genetics. Vandana Abramson has the following COI to disclose: Advisor/Consultation: Esai, Daiichi-Sankyo; Research funding: Genentech, Lily. Paula Pohlmann, M.D. has the following COI to disclose: Leadership: Immunonet BioSciences; Stock and other ownership interests: Immunonet BioSciences; Honoraria: Dava Oncology, ASCO; Consulting or advisory role: Personalized Cancer Therapy; Immunonet BioSciences, Sirtex, CARIS Lifesciences, OncoPlex Diagnostics, Pfizer, HERON, Puma Biotechnology, Juniper; Speakers’ Bureau: Genentech/Roche; Research Funding: Advanced Cancer Therapeutics (institution), Genentech/Roche (institution), Pieris Pharmaceuticals (institution), Cascadian Therapeutics (institution), Fabre-Kramer (institution), Pfizer (institution), Caris Centers of Excellence (institution); Patents, royalities, other intellectual property: U.S. patent numbers 9,745,377; 8,501,417; 8,486,413; 9,023,362. Catherine Van Poznak has the following COI to disclose: Research support from Bayer that is paid to my institution, University of Michigan. Andres Forero has the following COI to disclose: Employee with Seattle Genetics since 2018. Richard D. Gelber has the following COI to disclose: Research grants to my institutions from Roche, Novartis, Pfizer, Ferring, Celgene, AstraZeneca, Ipsen, GlaxoSmithKline. William Barry has the following COI to disclose: Funding (institution) from Pfizer (during the entire period of research for submitted work). No current conflicts of interest to declare. Eric P. Winer has the following COI to disclose: Consultant/advisor: Carrick Therapeutics, G1 Therapeutics, Genentech/Roche, Genomic Health/Exact Sciences, GSK, Jounce, Lilly, Novartis, Seattle Genetics, Syros and Leap. Institutional research funding from Genentech/Roche. Ian Krop has the following COI to disclose: Institutional research funding: Genentech/Roche, Pfizer, Daiichi-Sankyo; consultant/advisory board participant/DSMC/DSMB: Genentech/Roche, Daiichi-Sankyo, Macrogenics, Context Therapeutics, Taiho Oncology, Bristol-Myers Squibb, Celltrion Pharma, Merck, Novartis. Tal Sella, M.D. has the following COI to disclose: Honorarium from Roche within the past 3 years. Funding received for Dr. Sella’s fellowship supported by the Pinchas Borenstein Talpiot Medical Leadership Program Talpiot Medical Leadership Program, Sheba Medical Center, Israel and The American Physicians Fellowship for Medicine in Israel. Kathryn Ruddy, M.D., M.P.H. has the following COI to disclose: Sold Merck & Pfizer stock in 2/2018, receives royalties from UpToDate; and spouse is co-inventor of a technology licensed by Mayo Clinic to Alivecor.

: Institutional review board approval was obtained at Dana-Farber/Harvard Cancer Center (DF/HCC) and at all participating sites.